This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Poniard Predictions

BOSTON ( TheStreet) -- Let's open the Biotech Stock Mailbag, beginning with an email from Leslie O. about a very important event looming for Poniard Pharmaceuticals (PARD).

Writes Leslie, " Adam, what's your prediction for results from Poniard's phase III study of picoplatin in small cell lung cancer?"

I have no edge on this one, so I don't have a prediction for you. Needless to say, this is a huge event for Poniard. A successful study lands the company a partnership and a nice bump in the stock price. I'll guess in the $12-plus range. A negative outcome get reported, and Poniard shares will plummet towards cash levels of around $1. The stock was trading Thursday at around $7.

Poniard has guided to data before the end of November.

Picoplatin is a next-generation platinum chemotherapy drug designed to overcome resistance to prior platinum therapy. The drug may also cause less nerve-related toxicity.

The phase III study, dubbed "SPEAR," compares treatment with picoplatin against best supportive care (BSC) in second-line small cell lung cancer (SCLC) patients. These are patients with advanced, progressive disease after treatment with a front-line platinum agent. The primary endpoint of the study is overall survival.

The bull story: A published single-arm phase II study of picoplatin in SCLC patients demonstrated a median overall survival of 27 weeks. Best supportive care (BSC) in this patient population is believed to yield a median survival of around 14 weeks (again, from prior published studies.)

Poniard designed the SPEAR study conservatively so that picoplatin patients need only reach a 19-week median survival for the study to be a success, based on the assumption of a 14-week median survival for patients treated with BSC. Patients in the BSC arm are also prohibited from being treated with other chemotherapies in the second line, which could, in theory, hurt picoplatin's chances of showing a significant survival benefit.

1 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs